retatrutide type 2 diabetes trial results 2024 ESC 2024: improves lipid and cardiovascular risk profile in Phase II 💉 A triple-action once-weekly injection

Electrolyte supplementation can help manage the transition period

Since then, other GLP-1R agonists such as exenatide (Byetta ) and dulaglutide (Trulicity ) have been approve (Holman et al., 2017

Enhance Metabolic Health Optimize Digestive Wellness Increase Cellular Energy Improve Skin Clarity Reduce Bloating Support Weight Management Client Testimonials Real Feedback

Key topics to discuss include: Your fertility plans and timeline : If you are planning to conceive in the near future, your healthcare provider can advise on the appropriate timing for discontinuing GLP-1 medication

Past and current GLP-1 users (46% and 43%, respectively) were more likely to do so than non-users (25%)

Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study